EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC 4.0

Rapid start with bictegravir/emtricitabine/tenofovir alafenamide (B/F/ TAF ) as initial treatment in people with human immunodeficiency virus‐1 ( HIV ‐1): A systematic literature review of clinical and patient‐reported outcomes

Jade Ghosn iD, Jeremy Chow, Monica Gandhi, Miguel Górgolas, Aws Al-Hayani iD, Hansel Tookes, Max Lee, Emily F Kaiser, David Malebranche, Fernando Alvarez Bognar, Bhumi Gandhi-Patel iD, Lili Dai

HIV Medicine · 2025

DOI: 10.1111/hiv.70065 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift HIV Medicine, 2025. Verfasst von Jade Ghosn und 11 weiteren Autor:innen. Beteiligte Einrichtung: APHP.Nord, Hôpital Bichat Claude Bernard, Service des Maladies Infectieuses, Paris, France. Hauptthemen laut MEDLINE: HIV Infections, Emtricitabine, Tenofovir, Anti-HIV Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Treatment guidelines recommend rapid antiretroviral therapy (ART) initiation among eligible people with HIV to improve treatment outcomes and reduce HIV transmission. Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), an integrase strand transfer inhibitor‐based single‐tablet regimen, is recommended for rapid start in US and European guidelines. This systematic literature review synthesized evidence on the efficacy, safety and effect on patient‐reported outcomes (PROs) of B/F/TAF rapid start among newly diagnosed people with HIV.

Methods

MEDLINE, Embase, Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials databases were searched in January 2024, supplemented by searches of conference proceedings and clinical trial records. English‐language interventional studies of B/F/TAF rapid start among ART‐naïve people with HIV reporting efficacy, safety or PROs were eligible. Study quality was assessed using York Centre for Reviews and Dissemination or Risk Of Bias In Non‐randomized Studies of Interventions checklists. Results were synthesized narratively.

Results

Across eight included studies, 745 people with HIV received B/F/TAF rapid start, 171 received rapid start comparators and 255 received non‐rapid start comparators. At Weeks 24 and 48, 80%–94% and 74%–96% of people with HIV treated with B/F/TAF rapid start achieved viral load

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsEmtricitabineTenofovirAnti-HIV AgentsHeterocyclic Compounds, 4 or More RingsAdenineHumansHIV-1Patient Reported Outcome MeasuresPyridonesDrug CombinationsAlaninePiperazinesHeterocyclic Compounds, 3-RingTreatment OutcomeViral LoadAmides

Stichwörter der Autor:innen

adherenceengagement in careimmediate startquality of lifesafetyviral suppression

Substanzen

EmtricitabineTenofovirAnti-HIV AgentsbictegravirPyridonesDrug CombinationsAlanineHeterocyclic Compounds, 4 or More RingsPiperazinesAdenine

Autor:innen und Institutionen

  • APHP.Nord, Hôpital Bichat Claude Bernard, Service des Maladies Infectieuses, Paris, France.
  • Université Paris Cité, INSERM UMR 1137 IAME, Paris, France.
  • University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • University of California San Francisco, San Francisco, California, USA.
  • Fundación Jiménez Díaz, Madrid, Spain.
  • Fundación Jiménez Díaz, University Hospital, Madrid, Spain.

ORCID-Profile: Jade Ghosn, Aws Al-Hayani, Bhumi Gandhi-Patel

Förderung

  • Gilead Sciences

Zitieren

APA

Ghosn, J., Chow, J., Gandhi, M., Górgolas, M., Al-Hayani, A., Tookes, H., Lee, M., Kaiser, E. F., Malebranche, D., Bognar, F. A., Gandhi-Patel, B., & Dai, L. (2025). Rapid start with bictegravir/emtricitabine/tenofovir alafenamide (B/F/ TAF ) as initial treatment in people with human immunodeficiency virus‐1 ( HIV ‐1): A systematic literature review of clinical and patient‐reported outcomes. HIV Medicine. https://doi.org/10.1111/hiv.70065

Vancouver

Ghosn J, Chow J, Gandhi M, Górgolas M, Al-Hayani A, Tookes H, et al. Rapid start with bictegravir/emtricitabine/tenofovir alafenamide (B/F/ TAF ) as initial treatment in people with human immunodeficiency virus‐1 ( HIV ‐1): A systematic literature review of clinical and patient‐reported outcomes. HIV Medicine. 2025. doi:10.1111/hiv.70065

BibTeX
@article{Ghosn2025,
  author = {Ghosn, Jade and Chow, Jeremy and Gandhi, Monica and Górgolas, Miguel and Al-Hayani, Aws and Tookes, Hansel and Lee, Max and Kaiser, Emily F and Malebranche, David and Bognar, Fernando Alvarez and Gandhi-Patel, Bhumi and Dai, Lili},
  title = {Rapid start with bictegravir/emtricitabine/tenofovir alafenamide (B/F/ TAF ) as initial treatment in people with human immunodeficiency virus‐1 ( HIV ‐1): A systematic literature review of clinical and patient‐reported outcomes},
  journal = {HIV Medicine},
  year = {2025},
  doi = {10.1111/hiv.70065}
}
Kostenlos starten →